drug_type
RELEVANT_DRUG
intervention_type
Gene-modified cellular therapy (CAR T cells)
drug_description
Autologous anti-CD19 CAR T-cell therapy; gene-modified T cells that recognize and eliminate CD19+ B-lineage cells (naive/memory B cells, plasmablasts, some plasma cells) to reset humoral autoimmunity and reduce profibrotic signaling. Administered as a single infusion after lymphodepletion.
nci_thesaurus_concept_id
C175534
nci_thesaurus_preferred_term
Rapcabtagene Autoleucel
nci_thesaurus_definition
A preparation of autologous T-lymphocytes that are genetically engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon intravenous administration, rapcabtagene autoleucel is directed to and induces selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells genetically engineered to express an anti-CD19 chimeric antigen receptor. After infusion (post-lymphodepletion), the CAR T cells recognize CD19 on B-lineage cells and trigger T-cell activation and cytotoxic killing, resulting in depletion of CD19+ B cells (including naive/memory B cells and plasmablasts, some plasma cells). This resets humoral autoimmunity and, in oncology settings, eliminates CD19+ malignant cells.
drug_name
rapcabtagene autoleucel
nct_id_drug_ref
NCT06655896